Human Growth Hormone Research Paper

Tags: Prejudice Thesis StatementAn Evaluation EssayHigh School Science Essay QuestionsEssay On My Hobby PhotographyEasy Research PapersCompare And Contrast Essay On Macbeth And BeowulfHelp On College Essay Questions

Access to society journal content varies across our titles.

If you have access to a journal via a society or association membership, please browse to your society journal, select an article to view, and follow the instructions in this box.

Moore, MD, a pediatric endocrinologist at Children’s Mercy Hospital, Kansas City, Mo., presented the data at the annual meeting of the Endocrine Society.“Despite the fact that human growth hormone is a proven treatment for growth hormone deficiency, daily use of our current formulations can be a factor that affects compliance,” said Dr. He cited a 2008 Misperceptions about the consequences of missed doses and discomfort with injections were strongly associated with noncompliance, the authors of that paper noted.

Last year, the Growth Hormone Research Society a consensus paper calling for more research into longer-acting formulations (Eur J Endocrinol. The group of 55 international experts described several strategies for creating long-acting growth hormone formulations, including depot formulations, pegylation, prodrugs, noncovalent albumin binding growth hormone compounds, and growth hormone fusion proteins.

These findings were almost superimposable with those in the ANSWER registry. At baseline, the mean hemoglobin A was 5.2%; this was unchanged at 3 years. The most commonly reported adverse event was injection site pain (48%).

Bone age and chronological age came into alignment within the first year and that association was maintained throughout the study – again, in almost superimposable curves with the registry data. Injection site erythema was reported in 5% of patients, but no injection site nodules occurred.

The women taking estrogen experienced the flattest response, gaining about 2 SDs.

However, the response curve was nearly identical, with a rapid, sharp increase in IGF-1 within the first week, followed by a gradual decline to baseline by 22 days.

If they were on any growth hormone therapy, they underwent a 14-day washout period.

The subjects were divided and dosed by age and gender.